- Location
Ranbaxy Laboratories
"-
Ranbaxy Laboratories Has Secured Approval From CDSCO
Oct 23, 2013Ranbaxy Laboratories has secured approval from India's Central Drugs Standard Control Organisation (CDSCO) to manufacture and sell 'Synriam' to treat uncomplicated malaria caused by Plasmodium vivax parasite in adult patients. Phase III ...
Tags: Ranbaxy Laboratories, Drug Synriam
-
The EC Has Imposed a Fine of €146m on Nine Pharma Companies
Jun 21, 2013The European Commission (EC) has imposed a fine of €146m on nine pharma companies, including Ranbaxy Laboratories, for blocking the entry of cheaper generic drug of Lundbeck's anti-depressant, citalopram. Lundbeck agreed with each of ...
Tags: Ranbaxy, Halting Generic Drugs
-
Astrazeneca Has Suspended Expansion in The Chinese Generic Drug Market
Jun 3, 2013Leading global biopharmaceutical firm AstraZeneca has suspended expansion in the Chinese generic drug market. It announced adjustments on strategy for business in the Chinese mainland days ago and according to the adjustments, it will ...
Tags: Generic Drug Market, Health, Medicine
-
Synergistic Collaboration in Brazil to Expand Their Respective Businessess in The Country
Apr 22, 2013Daiichi Sankyo Company and Ranbaxy Laboratories have announced synergistic collaboration in Brazil to expand their respective businessess in the country. As part of the synergy, the companies will launch hybrid business model. Ranbaxy ...
Tags: Daiichi Sankyo Company, Medicine
-
Ranbaxy Laboratories Plans to Combine Business Operations in Thailand
Jan 18, 2013Daiichi Sankyo Company and Ranbaxy Laboratories have announced plans to combine business operations in Thailand. Both the companies plan to integrate the management of Daiichi Sankyo (Thailand) (DSTH) and Ranbaxy Unichem (RUCL), the ...
Tags: Daiichi Sankyo, Ranbaxy, Hybrid Business
-
Ranbaxy Laboratories Deployed Life Sciences Compliance Solution Suite
Jan 5, 2013Ranbaxy Laboratories has deployed Cegedim Relationship Management's Life Sciences compliance solution suite including AggregateSpend360 to meet growing regulatory environment. AggregateSpend360 is expected to relieve Ranbaxy of resources ...
Tags: Ranbaxy Laboratories, AggregateSpend360, OneKey, Medicine
-
Ranbaxy Has Introduced The Authorized Generic Cevimeline Hydrochloride 30mg Capsules in US
Nov 29, 2012Ranbaxy Pharmaceuticals (RPI), a wholly owned subsidiary of Ranbaxy Laboratories, has introduced the authorized generic cevimeline hydrochloride 30mg capsules in the US. Cevimeline hydrochloride is indicated for the treatment of dry mouth ...
Tags: Generic Evoxac, cevimeline hydrochloride, moisture-producing glands
-
Ranbaxy Laboratories Has Unveiled Synriam in India
Nov 29, 2012Ranbaxy Laboratories has unveiled Synriam in India, to treat uncomplicated Plasmodium falciparum malaria, in adults. The Drug Controller General of India approved the new drug, indicated for relief from malaria-related symptoms, for ...
Tags: Malaria Drug, Synriam, malaria
-
Ranbaxy Pharmaceuticals Launched Authorized Generic Pioglitazone Hydrochloride Tablets
Nov 28, 2012Ranbaxy Pharmaceuticals,a wholly owned subsidiary of Ranbaxy Laboratories(RLL),has launched authorized generic pioglitazone hydrochloride tablets in the US market under an agreement with Takeda Pharmaceuticals US. Pioglitazone ...
Tags: Ranbaxy Pharmaceuticals, Ranbaxy Laboratories, Takeda Pharmaceuticals
-
Teva Has Decided Not to Launch Atorvastatin, a Generic Version of Pfizer's Lipitor.
Nov 28, 2012Teva Pharmaceutical Industries has decided not to launch atorvastatin, a generic version of Pfizer's Lipitor. The decision will help Ranbaxy Laboratories and Dr Reddy's Laboratories gain larger sales of the medicine in the US, the ...
-
Ranbaxy Laboratories Has Launched Absorica (Isotretinoin) Capsules
Nov 27, 2012Research based pharmaceutical company Ranbaxy Laboratories has launched Absorica (Isotretinoin) Capsules, designed to treat severe recalcitrant nodular acne, in the US. Absoricais, which is licensed from Cipher Pharmaceuticals, can be ...
Tags: Absorica Capsules, nodular acne
-
Cipher Pharmaceuticals Has Received FDA Approval for Absorica
May 28, 2012Cipher Pharmaceuticals, a specialty pharmaceutical company, has received FDA approval for Absorica for the treatment of severe recalcitrant nodular acne. The company expects to launch its patented brand formulation of the acne ...